Abstract
Emerging evidence from epidemiological and randomized controlled trials (RCTs) support protective effects of foods and dietary supplements rich in flavonoids against cardiovascular disease (CVD). Epidemiological studies provide valuable information in this field but the estimation of flavonoid intake is still prone to bias due to limitations of food-frequency-questionnaires and lack of biomarkers. Advancements in mass spectrometry led to more accurate flavonoid quantification in foods and biological fluids and development of comprehensive metabolomic databases. Current research is still struggling with the establishment and validation of new biomarkers of flavonoid intake. Efforts to create adequate standardized materials and well-matched controls used in RCTs have also improved data robustness. However, the relationship between flavonoid intake and CVD is still not fully established.